BioSpace News Archive

Drug Development

Surrozen Pauses Phase I Trial Following Liver Enzyme Elevations

Surrozen announced it paused its Phase I study in Crohn’s disease and ulcerative colitis as several healthy participants showed increased levels of liver enzymes.

November 15, 2022
·
2 min read
·
Mark Terry
Business

Roche Doubles Down on Jnana’s RAPID Platform in $2B Deal (Updated)

Jnana Therapeutics forged its second small molecule discovery and development collaboration and licensing agreement with Roche valued at up to $2 billion.

November 15, 2022
·
2 min read
·
Alex Keown
Deals

Acrivon Becomes Biotech’s 20th IPO of 2022 with $99M Offering

Acrivon Therapeutics announced the pricing of its initial public offering Tuesday, putting all of its 7,550,000 shares of common stock up for sale for $12.50 apiece.

November 15, 2022
·
1 min read
·
Tristan Manalac
Drug Development

Roche Failure Leaves Industry Reassessing Alzheimer’s Space

When Roche announced that gantenerumab failed to meet the primary endpoint in two Phase III studies, several of its competitors saw their stocks rise - including Biogen and Eisai.

November 15, 2022
·
4 min read
·
Heather McKenzie
Drug Development

Beyond COVID-19 and RSV, Emerging Vaccines Target Less Common Conditions

RSV, influenza, COVID-19 and monkeypox have dominated vaccine discussions this year, but vaccines are also being developed for a host of other infectious diseases.

November 15, 2022
·
5 min read
·
Gail Dutton
FDA

FDA Approves First-Ever ADC in Platinum-Resistant Ovarian Cancer (Updated)

ImmunoGen’s Elahere was approved Monday under the FDA’s accelerated pathway for patients who have received one to three previous lines of systemic therapy.

November 15, 2022
·
2 min read
·
Tristan Manalac
Business

Good Therapeutics’ Offshoot Bonum Launches with $93 Million in Series A (Updated)

Two months after selling an immuno-oncology platform developed by Good Therapeutics to Roche, Bonum Therapeutics launched Tuesday with $93 million in Series A financing.

November 15, 2022
·
2 min read
·
Alex Keown
Drug Development

Beam Enrolls Trial’s First Patient in “Step Forward” for Base Editing

Beam Therapeutics has enrolled the first patient in a Phase I/II trial studying a gene therapy leveraging base editing in adults with severe sickle cell disease.

November 15, 2022
·
2 min read
·
Rosemary Scott
Drug Development

Neoleukin Drops de Novo Protein Therapeutic, Slashes Workforce - Updated

Neoleukin Therapeutics plans to slash its workforce by about 40% and drop NL-201, a de novo IL-2/IL-15 agonist currently in Phase I, according to its third-quarter report.

November 15, 2022
·
2 min read
·
Rosemary Scott
Business

NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets.

November 15, 2022
·
3 min read